Fasenra Approved for Treatment of Children Aged 6 to 11 with Severe Asthma
Fasenra Approved for Treatment of Children Aged 6 to 11 with Severe Asthma
Fasenra Approved for Treatment of Children Aged 6 to 11 with Severe Asthma
ViiV Healthcare Announces U.S. FDA Approval of Dovato (dolutegravir/lamivudine) for Adolescents Living with HIV
Endoscopic Sleeve Gastroplasty Is Cost Saving Versus Semaglutide
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for Iclusig (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL